Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A FREEDMAN

Showing results (851-860 of 916) with videos related to

Pageof 92
Sort By:
Cell Host & Microbe|July 11, 2015
Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface ExpressionKirk J Lubick, Shelly J Robertson, Kristin L McNally, et al.
The Journal of the American Academy of Orthopaedic Surgeons|July 15, 2024
Factors Related to Clinical Performance in Spine Surgery Fellowship: Can We Predict SuccessHannah A Levy, Payton Boere, Zane Randell, et al.
Clinical Spine Surgery|October 3, 2022
A Prospective Study of Lumbar Facet Arthroplasty in the Treatment of Degenerative Spondylolisthesis and Stenosis: Results from the Total Posterior Spine System (TOPS) IDE StudyZachariah W Pinter, Brett A Freedman, Ahmad Nassr, et al.
Journal of the National Cancer Institute|April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapyChristina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
JAMA Oncology|February 17, 2017
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical TrialsEthan Basch, Amylou C Dueck, Lauren J Rogak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2024
Spectrum of somatic mutational features of colorectal tumors in ancestrally diverse populationsMarco Matejcic, Jamie K Teer, Hannah J Hoehn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Pageof 92

Showing results (851-860 of 916) with videos related to

Sort By:
Pageof 92
Cell Host & Microbe|July 11, 2015
Flavivirus Antagonism of Type I Interferon Signaling Reveals Prolidase as a Regulator of IFNAR1 Surface ExpressionKirk J Lubick, Shelly J Robertson, Kristin L McNally, et al.
The Journal of the American Academy of Orthopaedic Surgeons|July 15, 2024
Factors Related to Clinical Performance in Spine Surgery Fellowship: Can We Predict SuccessHannah A Levy, Payton Boere, Zane Randell, et al.
Clinical Spine Surgery|October 3, 2022
A Prospective Study of Lumbar Facet Arthroplasty in the Treatment of Degenerative Spondylolisthesis and Stenosis: Results from the Total Posterior Spine System (TOPS) IDE StudyZachariah W Pinter, Brett A Freedman, Ahmad Nassr, et al.
Journal of the National Cancer Institute|April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapyChristina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.
Cell Genomics|September 10, 2025
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNAHeather A Parsons, Conor Messer, Katheryn Santos, et al.
JAMA Oncology|February 17, 2017
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical TrialsEthan Basch, Amylou C Dueck, Lauren J Rogak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2016
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain MetastasesRachel A Freedman, Rebecca S Gelman, Jeffrey S Wefel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast CancerCynthia X Ma, Jingqin Luo, Rachel A Freedman, et al.
Medrxiv : the Preprint Server for Health Sciences|April 1, 2024
Spectrum of somatic mutational features of colorectal tumors in ancestrally diverse populationsMarco Matejcic, Jamie K Teer, Hannah J Hoehn, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|July 5, 2014
Occult primary, version 3.2014David S Ettinger, Charles R Handorf, Mark Agulnik, et al.
Pageof 92